CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Listen to Julio C. Chavez, MD, MS, a medical oncologist based in an academic center, and Alan Skarbnik, MD, a medical oncologist based in the community, discuss the emerging role of CELMoDs in non-Hodgkin lymphoma care, including available data and ongoing clinical trials with these agents.
Decera Clinical Education Oncology Podcast · Julio C. Chavez MD MS, Alan Skarbnik MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:
- Rationale for targeting CELMoDs in NHL
- Mechanism of action of CELMoDs
- Key studies and available efficacy and safety data with investigational CELMoDs in NHL
- Key ongoing clinical trials of CELMoDs in NHL
- Strategies to boost NHL clinical trial diversity among underserved communities
Presenters:
Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida
Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.
Link to full program:
https://bit.ly/45YXoZI
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.